Albert David Ltd

Albert David Ltd maintains a strong liquidity position, with a current ratio of 3.75, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score of 0.94 suggests a high level of financial flexibility, supported by INR 257.22 million in cash and equivalents and a low debt-to-equity ratio of 0.01. In terms of profitability, the company's return on equity (ROE) of 3.37% and return on assets (ROA) of 2.59% are below the industry median for pharmaceutical firms, which typically report ROE and ROA in the 8-12% and 4-6% ranges, respectively. This suggests that Albert David Ltd is underperforming in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a few key markets, with the majority of its INR 890.58 million in revenue derived from India and the Middle East. There is no significant diversification into other geographic regions, which could expose the company to regional economic or regulatory risks. Looking ahead, the company's revenue is projected to grow by 4.2% in the current fiscal year and 3.8% in the next fiscal year, based on historical revenue trends and industry growth expectations. However, this growth is modest compared to the industry average of 6-8%. The company's risk profile is relatively low, with no immediate liquidity or dilution flags detected. The dilution_potential_basic is rated as low, and no recent equity issuance or ATM/shelf registration has been reported. The company's capital structure remains stable, with minimal long-term debt and a strong equity base. Recent filings and transcripts indicate that Albert David Ltd has not disclosed any major strategic shifts or new product launches in the past 12 months. The company continues to focus on its core markets and has not announced any significant R&D investments or expansion plans.